Pharmaceutics
Cure8 research brief
Why This Matters
Colon-targeted prednisolone devices could lower upper-GI exposure to steroids and provide sustained local therapy, which may be relevant for IBD treatment strategies if later validated in vivo and in clinical trials.
Who Should Pay Attention
Researchers (drug-delivery, formulation), clinicians interested in localized IBD therapies, and translational scientists.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers used fused deposition modeling to produce two device types that carry either prednisolone tablets or prednisolone gel, then coated them with Eudragit S100.
In vitro dissolution tests in simulated gastric (pH 1.2), intestinal (pH 6.8) and colonic (pH 7.4) media showed negligible release in gastric and intestinal conditions and onset of sustained release under colonic conditions over ~24 hours. The work is an in vitro, formulation-development study reported as an abstract/full-text in Pharmaceutics.
The findings show proof-of-concept under laboratory dissolution testing; they do not demonstrate safety or efficacy in animals or people.
Keep In Mind
Results are based on in vitro dissolution testing using simulated fluids and an enteric polymer (Eudragit S100). No in vivo or clinical data are reported in this article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPharmaceutics
AuthorsJaiseri D, Pengnam S, Opanasopit P +7 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 19, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Thailand Science Research and Innovation (TSRI) National Science, Research and Innovation Fund (NSRF) (Fiscal Year 2025); National Research Council of Thailand - N41A661139
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Efficient Preparation of pH-Sensitive Core-Shell Drug-Loaded Hydrogel Microcapsules and Their Application in Ulcerative Colitis Treatment.
A colon-targeted microcapsule could improve how drugs reach inflamed tissue in ulcerative colitis, potentially reducing stomach degradation and systemic side effects while increasing local effect.
Development and Evaluation of Carvacrol-Pectin/Chitosan Complex for Colon Targeted Drug Delivery in Ulcerative Colitis
New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...
Orally administrable photo-crosslinked coumaroyl-modified gelatin-CNC nanofibers for ulcerative colitis environment-triggered release of 5-aminosalicylic acid
Targeted release of mesalamine to the colon could increase local drug levels and reduce upper-GI exposure and systemic side effects. New delivery platforms may improve effectiveness for ulcerative colitis without...